{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T06:52:48Z","timestamp":1794293568661,"version":"4.9.0"},"reference-count":196,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1038\/s41571-022-00600-w","type":"journal-article","created":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T09:03:43Z","timestamp":1643187823000},"page":"254-267","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":969,"title":["Immune-checkpoint inhibitors: long-term implications of toxicity"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-773X","authenticated-orcid":false,"given":"Douglas B.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline A.","family":"Nebhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javid J.","family":"Moslehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4263-5974","authenticated-orcid":false,"given":"Justin M.","family":"Balko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,26]]},"reference":[{"key":"600_CR1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","volume":"2","author":"A Haslam","year":"2019","unstructured":"Haslam, A. & Prasad, V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw. Open. 2, e192535 (2019).","journal-title":"JAMA Netw. Open."},{"key":"600_CR2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1189\/jlb.5RI0116-013RR","volume":"100","author":"AE Vilgelm","year":"2016","unstructured":"Vilgelm, A. E., Johnson, D. B. & Richmond, A. Combinatorial approach to cancer immunotherapy: strength in numbers. J. Leukoc. Biol. 100, 275\u2013290 (2016).","journal-title":"J. Leukoc. Biol."},{"key":"600_CR3","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","volume":"5","author":"SL Topalian","year":"2019","unstructured":"Topalian, S. L. et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab. JAMA Oncol. 5, 1411\u20131420 (2019).","journal-title":"JAMA Oncol."},{"key":"600_CR4","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","volume":"19","author":"CU Blank","year":"2019","unstructured":"Blank, C. U. et al. Defining \u2018T cell exhaustion\u2019. Nat. Rev. Immunol. 19, 665\u2013674 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"600_CR5","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nature22367","volume":"545","author":"M Philip","year":"2017","unstructured":"Philip, M. et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature 545, 452\u2013456 (2017).","journal-title":"Nature"},{"key":"600_CR6","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1189\/jlb.1A0316-135R","volume":"101","author":"BM Barton","year":"2017","unstructured":"Barton, B. M., Xu, R., Wherry, E. J. & Porrett, P. M. Pregnancy promotes tolerance to future offspring by programming selective dysfunction in long-lived maternal T cells. J. Leukoc. Biol. 101, 975\u2013987 (2017).","journal-title":"J. Leukoc. Biol."},{"key":"600_CR7","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.kint.2020.03.037","volume":"98","author":"YJ Shim","year":"2020","unstructured":"Shim, Y. J. et al. Early T cell infiltration is modulated by programed cell death-1 protein and its ligand (PD-1\/PD-L1) interactions in murine kidney transplants. Kidney Int. 98, 897\u2013905 (2020).","journal-title":"Kidney Int."},{"key":"600_CR8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/2326-6066.CIR-13-0013","volume":"1","author":"MJ Selby","year":"2013","unstructured":"Selby, M. J. et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol. Res. 1, 32\u201342 (2013).","journal-title":"Cancer Immunol. Res."},{"key":"600_CR9","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"600_CR10","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"600_CR11","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.4049\/jimmunol.157.9.3869","volume":"157","author":"B Saha","year":"1996","unstructured":"Saha, B. et al. Toxic shock syndrome toxin-1-induced death is prevented by CTLA4Ig. J. Immunol. 157, 3869\u20133875 (1996).","journal-title":"J. Immunol."},{"key":"600_CR12","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","volume":"270","author":"P Waterhouse","year":"1995","unstructured":"Waterhouse, P. et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270, 985\u2013988 (1995).","journal-title":"Science"},{"key":"600_CR13","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","volume":"3","author":"EA Tivol","year":"1995","unstructured":"Tivol, E. A. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3, 541\u2013547 (1995).","journal-title":"Immunity"},{"key":"600_CR14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","volume":"11","author":"H Nishimura","year":"1999","unstructured":"Nishimura, H. et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11, 141\u2013151 (1999).","journal-title":"Immunity"},{"key":"600_CR15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","volume":"291","author":"H Nishimura","year":"2001","unstructured":"Nishimura, H. et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291, 319\u2013322 (2001).","journal-title":"Science"},{"key":"600_CR16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1200\/JCO.19.01381","volume":"38","author":"AA Tarhini","year":"2020","unstructured":"Tarhini, A. A. et al. Phase III study of adjuvant ipilimumab (3 or 10 mg\/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma: North American Intergroup E1609. J. Clin. Oncol. 38, 567\u2013575 (2020).","journal-title":"J. Clin. Oncol."},{"key":"600_CR17","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1200\/JCO.20.02110","volume":"38","author":"AMM Eggermont","year":"2020","unstructured":"Eggermont, A. M. M. et al. Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG\/KEYNOTE-054 trial. J. Clin. Oncol. 38, 3925\u20133936 (2020).","journal-title":"J. Clin. Oncol."},{"key":"600_CR18","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber, J. et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med. 377, 1824\u20131835 (2017).","journal-title":"N. Engl. J. Med."},{"key":"600_CR19","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010).","journal-title":"N. Engl. J. Med."},{"key":"600_CR20","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377, 2500\u20132501 (2017).","journal-title":"N. Engl. J. Med."},{"key":"600_CR21","first-page":"175883592093761","volume":"12","author":"B Zhao","year":"2020","unstructured":"Zhao, B., Zhao, H. & Zhao, J. Efficacy of PD-1\/PD-L1 blockade monotherapy in clinical trials. Ther. Adv. Med. Oncol. 12, 1758835920937612 (2020).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"600_CR22","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535\u20131546 (2019).","journal-title":"N. Engl. J. Med."},{"key":"600_CR23","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277\u20131290 (2018).","journal-title":"N. Engl. J. Med."},{"key":"600_CR24","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803\u20131813 (2015).","journal-title":"N. Engl. J. Med."},{"key":"600_CR25","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1080\/14712598.2021.1921140","volume":"21","author":"SK Wong","year":"2021","unstructured":"Wong, S. K., Beckermann, K. E., Johnson, D. B. & Das, S. Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy. Expert Opin. Biol. Ther. 21, 1623\u20131634 (2021).","journal-title":"Expert Opin. Biol. Ther."},{"key":"600_CR26","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345\u20131356 (2017).","journal-title":"N. Engl. J. Med."},{"key":"600_CR27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23\u201334 (2015).","journal-title":"N. Engl. J. Med."},{"key":"600_CR28","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1200\/JCO.20.00131","volume":"38","author":"DM Waterhouse","year":"2020","unstructured":"Waterhouse, D. M. et al. Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer: CheckMate 153. J. Clin. Oncol. 38, 3863\u20133873 (2020).","journal-title":"J. Clin. Oncol."},{"key":"600_CR29","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/annonc\/mdz110","volume":"30","author":"YJL Jansen","year":"2019","unstructured":"Jansen, Y. J. L. et al. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Ann. Oncol. 30, 1154\u20131161 (2019).","journal-title":"Ann. Oncol."},{"key":"600_CR30","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","volume":"36","author":"C Robert","year":"2018","unstructured":"Robert, C. et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J. Clin. Oncol. 36, 1668\u20131674 (2018).","journal-title":"J. Clin. Oncol."},{"key":"600_CR31","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1200\/JCO.19.01464","volume":"38","author":"A Betof Warner","year":"2020","unstructured":"Betof Warner, A. et al. Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade. J. Clin. Oncol. 38, 1655\u20131663 (2020).","journal-title":"J. Clin. Oncol."},{"key":"600_CR32","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120360","volume":"3","author":"DB Johnson","year":"2018","unstructured":"Johnson, D. B. et al. Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3\/FCRL6 engagement. JCI Insight 3, e120360 (2018).","journal-title":"JCI Insight"},{"key":"600_CR33","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819\u2013829 (2016).","journal-title":"N. Engl. J. Med."},{"key":"600_CR34","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-01062-w","volume":"8","author":"M Sade-Feldman","year":"2017","unstructured":"Sade-Feldman, M. et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat. Commun. 8, 1136 (2017).","journal-title":"Nat. Commun."},{"key":"600_CR35","doi-asserted-by":"crossref","first-page":"1862948","DOI":"10.1080\/2162402X.2020.1862948","volume":"10","author":"T Kato","year":"2021","unstructured":"Kato, T. et al. Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma. Oncoimmunology 10, 1862948 (2021).","journal-title":"Oncoimmunology"},{"key":"600_CR36","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1158\/1078-0432.CCR-19-2244","volume":"26","author":"I Spassova","year":"2020","unstructured":"Spassova, I. et al. Predominance of central memory T cells with high T-cell receptor repertoire diversity is associated with response to PD-1\/PD-L1 inhibition in Merkel cell carcinoma. Clin. Cancer Res. 26, 2257\u20132267 (2020).","journal-title":"Clin. Cancer Res."},{"key":"600_CR37","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s43018-021-00180-1","volume":"2","author":"J Han","year":"2021","unstructured":"Han, J. et al. Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy. Nat. Cancer 2, 300\u2013311 (2021).","journal-title":"Nat. Cancer"},{"key":"600_CR38","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167\u20133175 (2010).","journal-title":"J. Clin. Oncol."},{"key":"600_CR39","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","volume":"21","author":"A Patnaik","year":"2015","unstructured":"Patnaik, A. et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin. Cancer Res. 21, 4286\u20134293 (2015).","journal-title":"Clin. Cancer Res."},{"key":"600_CR40","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","volume":"7","author":"S Das","year":"2019","unstructured":"Das, S. & Johnson, D. B. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J. Immunother. Cancer 7, 306 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"600_CR41","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2019.0046","volume":"5","author":"HT Quach","year":"2019","unstructured":"Quach, H. T. et al. Association of anti-programmed cell death 1 cutaneous toxic effects with outcomes in patients with advanced melanoma. JAMA Oncol. 5, 906\u2013908 (2019).","journal-title":"JAMA Oncol."},{"key":"600_CR42","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","volume":"6","author":"AMM Eggermont","year":"2020","unstructured":"Eggermont, A. M. M. et al. Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncol. 6, 519\u2013527 (2020).","journal-title":"JAMA Oncol."},{"key":"600_CR43","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","volume":"5","author":"F Berner","year":"2019","unstructured":"Berner, F. et al. Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer. JAMA Oncol. 5, 1043\u20131047 (2019).","journal-title":"JAMA Oncol."},{"key":"600_CR44","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson, D. B. et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375, 1749\u20131755 (2016).","journal-title":"N. Engl. J. Med."},{"key":"600_CR45","doi-asserted-by":"crossref","first-page":"100064","DOI":"10.1016\/j.esmoop.2021.100064","volume":"6","author":"M Guida","year":"2021","unstructured":"Guida, M. et al. Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study. ESMO Open 6, 100064 (2021).","journal-title":"ESMO Open"},{"key":"600_CR46","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/s41591-019-0523-2","volume":"25","author":"DB Johnson","year":"2019","unstructured":"Johnson, D. B. et al. A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nat. Med. 25, 1243\u20131250 (2019).","journal-title":"Nat. Med."},{"key":"600_CR47","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10391","volume":"7","author":"K Dubin","year":"2016","unstructured":"Dubin, K. et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat. Commun. 7, 10391 (2016).","journal-title":"Nat. Commun."},{"key":"600_CR48","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","volume":"6","author":"S Iwama","year":"2014","unstructured":"Iwama, S. et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci. Transl. Med. 6, 230ra45 (2014).","journal-title":"Sci. Transl. Med."},{"key":"600_CR49","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1158\/2159-8290.CD-20-0856","volume":"11","author":"SC Wei","year":"2021","unstructured":"Wei, S. C. et al. A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention. Cancer Discov. 11, 614\u2013625 (2021).","journal-title":"Cancer Discov."},{"key":"600_CR50","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","volume":"182","author":"AM Luoma","year":"2020","unstructured":"Luoma, A. M. et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell 182, 655\u2013671.e22 (2020).","journal-title":"Cell"},{"key":"600_CR51","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-021-01406-6","volume":"27","author":"MC Andrews","year":"2021","unstructured":"Andrews, M. C. et al. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat. Med. 27, 1432\u20131441 (2021).","journal-title":"Nat. Med."},{"key":"600_CR52","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1172\/JCI96798","volume":"128","author":"R Das","year":"2018","unstructured":"Das, R. et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J. Clin. Invest. 128, 715\u2013720 (2018).","journal-title":"J. Clin. Invest."},{"key":"600_CR53","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb7495","volume":"13","author":"Y Yasuda","year":"2021","unstructured":"Yasuda, Y. et al. CD4+ T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice. Sci. Transl. Med. 13, eabb7495 (2021).","journal-title":"Sci. Transl. Med."},{"key":"600_CR54","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1200\/JCO.2019.37.15_suppl.2616","volume":"37","author":"DH Johnson","year":"2019","unstructured":"Johnson, D. H. et al. Interleukin-6 is potential target to de-couple checkpoint inhibitor-induced colitis from antitumor immunity. J. Clin. Oncol. 37, 2616 (2019).","journal-title":"J. Clin. Oncol."},{"key":"600_CR55","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/1078155217745144","volume":"25","author":"CR Stroud","year":"2019","unstructured":"Stroud, C. R. et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J. Oncol. Pharm. Pract. 25, 551\u2013557 (2019).","journal-title":"J. Oncol. Pharm. Pract."},{"key":"600_CR56","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158\u2013168 (2018).","journal-title":"N. Engl. J. Med."},{"key":"600_CR57","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1001\/jama.2018.13995","volume":"320","author":"DB Johnson","year":"2018","unstructured":"Johnson, D. B., Chandra, S. & Sosman, J. A. Immune checkpoint inhibitor toxicity in 2018. JAMA 320, 1702\u20131703 (2018).","journal-title":"JAMA"},{"key":"600_CR58","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","volume":"35","author":"JS Weber","year":"2017","unstructured":"Weber, J. S. et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J. Clin. Oncol. 35, 785\u2013792 (2017).","journal-title":"J. Clin. Oncol."},{"key":"600_CR59","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","volume":"18","author":"JA Thompson","year":"2020","unstructured":"Thompson, J. A. et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020. J. Natl Compr. Canc Netw. 18, 230\u2013241 (2020).","journal-title":"J. Natl Compr. Canc Netw."},{"key":"600_CR60","doi-asserted-by":"crossref","first-page":"002435e","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer, J. R. et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J. Immunother. Cancer 9, 002435e (2021).","journal-title":"J. Immunother. Cancer"},{"key":"600_CR61","doi-asserted-by":"crossref","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","volume":"29","author":"J Haanen","year":"2018","unstructured":"Haanen, J. et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29, iv264\u2013iv266 (2018).","journal-title":"Ann. Oncol."},{"key":"600_CR62","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1158\/1078-0432.CCR-21-1283","volume":"27","author":"X Bai","year":"2021","unstructured":"Bai, X. et al. Early use of high-dose glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy. Clin. Cancer Res. 27, 5993\u20136000 (2021).","journal-title":"Clin. Cancer Res."},{"key":"600_CR63","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejca.2021.04.045","volume":"153","author":"H Dearden","year":"2021","unstructured":"Dearden, H. et al. Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. Eur. J. Cancer 153, 168\u2013178 (2021).","journal-title":"Eur. J. Cancer"},{"key":"600_CR64","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.annonc.2021.03.204","volume":"32","author":"CN Owen","year":"2021","unstructured":"Owen, C. N. et al. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Ann. Oncol. 32, 917\u2013925 (2021).","journal-title":"Ann. Oncol."},{"key":"600_CR65","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.annonc.2021.10.003","volume":"33","author":"F Dimitriou","year":"2021","unstructured":"Dimitriou, F. et al. FDG-PET to predict long-term outcome from anti-PD1 therapy in metastatic melanoma. Ann. Oncol. 33, 99\u2013106 (2021).","journal-title":"Ann. Oncol."},{"key":"600_CR66","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/annonc\/mdx717","volume":"29","author":"RJ Lee","year":"2018","unstructured":"Lee, R. J. et al. Circulating tumor DNA predicts survival in patients with resected high-risk stage II\/III melanoma. Ann. Oncol. 29, 490\u2013496 (2018).","journal-title":"Ann. Oncol."},{"key":"600_CR67","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","volume":"37","author":"PA Ott","year":"2019","unstructured":"Ott, P. A. et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J. Clin. Oncol. 37, 318\u2013327 (2019).","journal-title":"J. Clin. Oncol."},{"key":"600_CR68","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1001\/jamaoncol.2021.0051","volume":"7","author":"JR Patrinely Jr","year":"2021","unstructured":"Patrinely, J. R. Jr et al. Chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma. JAMA Oncol. 7, 744\u2013748 (2021).","journal-title":"JAMA Oncol."},{"key":"600_CR69","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/cncr.32542","volume":"126","author":"LX Wang","year":"2020","unstructured":"Wang, L. X. et al. Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors. Cancer 126, 322\u2013328 (2020).","journal-title":"Cancer"},{"key":"600_CR70","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1158\/2326-6066.CIR-14-0217","volume":"3","author":"DB Johnson","year":"2015","unstructured":"Johnson, D. B. et al. Survivorship in immune therapy: assessing chronic immune toxicities, health outcomes, and functional status among long-term ipilimumab survivors at a single referral center. Cancer Immunol. Res. 3, 464\u2013469 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"600_CR71","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejca.2020.05.005","volume":"135","author":"JR Patrinely Jr","year":"2020","unstructured":"Patrinely, J. R. Jr et al. Survivorship in immune therapy: assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand. Eur. J. Cancer 135, 211\u2013220 (2020).","journal-title":"Eur. J. Cancer"},{"key":"600_CR72","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1530\/EJE-19-0238","volume":"181","author":"A Faje","year":"2019","unstructured":"Faje, A. et al. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur. J. Endocrinol. 181, 211\u2013219 (2019).","journal-title":"Eur. J. Endocrinol."},{"key":"600_CR73","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","volume":"124","author":"AT Faje","year":"2018","unstructured":"Faje, A. T. et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer 124, 3706\u20133714 (2018).","journal-title":"Cancer"},{"key":"600_CR74","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41584-020-00546-2","volume":"17","author":"LC Cappelli","year":"2021","unstructured":"Cappelli, L. C. & Bingham, C. O. 3rd Spectrum and impact of checkpoint inhibitor-induced irAEs. Nat. Rev. Rheumatol. 17, 69\u201370 (2021).","journal-title":"Nat. Rev. Rheumatol."},{"key":"600_CR75","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/2326-6066.CIR-18-0613","volume":"7","author":"C Ma","year":"2019","unstructured":"Ma, C. et al. The impact of high-dose glucocorticoids on the outcome of immune-checkpoint inhibitor-related thyroid disorders. Cancer Immunol. Res. 7, 1214\u20131220 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"600_CR76","first-page":"17","volume":"40","author":"JJ Wright","year":"2021","unstructured":"Wright, J. J., Powers, A. C. & Johnson, D. B. Endocrine toxicities of immune checkpoint inhibitors. Nat. Rev. Endocrinol. 40, 17\u201365 (2021).","journal-title":"Nat. Rev. Endocrinol."},{"key":"600_CR77","doi-asserted-by":"crossref","first-page":"e3704","DOI":"10.1210\/clinem\/dgab263","volume":"106","author":"CA Muir","year":"2021","unstructured":"Muir, C. A. et al. Thyroid immune-related adverse events following immune checkpoint inhibitor treatment. J. Clin. Endocrinol. Metab. 106, e3704\u2013e3713 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"600_CR78","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1089\/thy.2018.0116","volume":"28","author":"PC Iyer","year":"2018","unstructured":"Iyer, P. C. et al. Immune-related thyroiditis with immune checkpoint inhibitors. Thyroid 28, 1243\u20131251 (2018).","journal-title":"Thyroid"},{"key":"600_CR79","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/2326-6066.CIR-17-0208","volume":"5","author":"H Lee","year":"2017","unstructured":"Lee, H. et al. Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy. Cancer Immunol. Res. 5, 1133\u20131140 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"600_CR80","volume":"5","author":"MH Tan","year":"2019","unstructured":"Tan, M. H. et al. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. Clin. Diabetes Endocrinol. 5, 1 (2019).","journal-title":"Clin. Diabetes Endocrinol."},{"key":"600_CR81","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4158\/EP-2019-0244","volume":"26","author":"M Al Mushref","year":"2020","unstructured":"Al Mushref, M. et al. Thyroid dysfunction, recovery, and prognosis in melanoma patients treated with immune checkpoint inhibitors: a retrospective review. Endocr. Pract. 26, 36\u201342 (2020).","journal-title":"Endocr. Pract."},{"key":"600_CR82","first-page":"2140","volume":"18","author":"T Sakakida","year":"2019","unstructured":"Sakakida, T. et al. Clinical features of immune-related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PD-1 blockade. Oncol. Lett. 18, 2140\u20132147 (2019).","journal-title":"Oncol. Lett."},{"key":"600_CR83","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.annonc.2021.05.357","volume":"32","author":"S Street","year":"2021","unstructured":"Street, S. et al. The positive effect of immune checkpoint inhibitor-induced thyroiditis on overall survival accounting for immortal time bias: a retrospective cohort study of 6,596 patients. Ann. Oncol. 32, 1050\u20131051 (2021).","journal-title":"Ann. Oncol."},{"key":"600_CR84","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56026-5","volume":"9","author":"J Garon-Czmil","year":"2019","unstructured":"Garon-Czmil, J. et al. Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French Pharmacovigilance database. Sci. Rep. 9, 19419 (2019).","journal-title":"Sci. Rep."},{"key":"600_CR85","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","volume":"51","author":"J de Filette","year":"2019","unstructured":"de Filette, J. et al. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm. Metab. Res. 51, 145\u2013156 (2019).","journal-title":"Horm. Metab. Res."},{"key":"600_CR86","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1210\/jc.2019-00423","volume":"104","author":"VHM Tsang","year":"2019","unstructured":"Tsang, V. H. M. et al. Checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes. J. Clin. Endocrinol. Metab. 104, 5499\u20135506 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"600_CR87","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.2337\/dc18-1465","volume":"41","author":"JJ Wright","year":"2018","unstructured":"Wright, J. J. et al. Increased reporting of immune checkpoint inhibitor-associated diabetes. Diabetes Care 41, e150\u2013e151 (2018).","journal-title":"Diabetes Care"},{"key":"600_CR88","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","volume":"67","author":"AM Stamatouli","year":"2018","unstructured":"Stamatouli, A. M. et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes 67, 1471\u20131480 (2018).","journal-title":"Diabetes"},{"key":"600_CR89","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1634\/theoncologist.2019-0555","volume":"25","author":"V Grouthier","year":"2020","unstructured":"Grouthier, V. et al. Immune checkpoint inhibitor-associated primary adrenal insufficiency: WHO VigiBase Report Analysis. Oncologist 25, 696\u2013701 (2020).","journal-title":"Oncologist"},{"key":"600_CR90","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2021.04.031","volume":"152","author":"M Salzmann","year":"2021","unstructured":"Salzmann, M. et al. Male fertility during and after immune checkpoint inhibitor therapy: a cross-sectional pilot study. Eur. J. Cancer 152, 41\u201348 (2021).","journal-title":"Eur. J. Cancer"},{"key":"600_CR91","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1001\/jamaoncol.2020.1641","volume":"6","author":"JM Scovell","year":"2020","unstructured":"Scovell, J. M. et al. Association of impaired spermatogenesis with the use of immune checkpoint inhibitors in patients with metastatic melanoma. JAMA Oncol. 6, 1297\u20131299 (2020).","journal-title":"JAMA Oncol."},{"key":"600_CR92","doi-asserted-by":"crossref","first-page":"102586","DOI":"10.1016\/j.autrev.2020.102586","volume":"19","author":"Y Allenbach","year":"2020","unstructured":"Allenbach, Y. et al. Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmun. Rev. 19, 102586 (2020).","journal-title":"Autoimmun. Rev."},{"key":"600_CR93","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.semarthrit.2018.02.011","volume":"48","author":"LC Cappelli","year":"2018","unstructured":"Cappelli, L. C. et al. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Semin. Arthritis Rheum. 48, 553\u2013557 (2018).","journal-title":"Semin. Arthritis Rheum."},{"key":"600_CR94","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2017-211216","volume":"76","author":"R Belkhir","year":"2017","unstructured":"Belkhir, R. et al. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann. Rheum. Dis. 76, 1747\u20131750 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"600_CR95","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1634\/theoncologist.2016-0390","volume":"22","author":"J Naidoo","year":"2017","unstructured":"Naidoo, J. et al. Inflammatory arthritis: a newly recognized adverse event of immune checkpoint blockade. Oncologist 22, 627\u2013630 (2017).","journal-title":"Oncologist"},{"key":"600_CR96","first-page":"696","volume":"25","author":"TJ Braaten","year":"2019","unstructured":"Braaten, T. J. et al. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann. Rheum. Dis. 25, 696\u2013701 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"600_CR97","doi-asserted-by":"crossref","first-page":"102595","DOI":"10.1016\/j.autrev.2020.102595","volume":"19","author":"J Roberts","year":"2020","unstructured":"Roberts, J. et al. Rheumatic immune-related adverse events associated with cancer immunotherapy: a nationwide multi-center cohort. Autoimmun. Rev. 19, 102595 (2020).","journal-title":"Autoimmun. Rev."},{"key":"600_CR98","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s41927-020-00133-8","volume":"4","author":"LC Cappelli","year":"2020","unstructured":"Cappelli, L. C. et al. Immune checkpoint inhibitor-induced inflammatory arthritis: a qualitative study identifying unmet patient needs and care gaps. BMC Rheumatol. 4, 32 (2020).","journal-title":"BMC Rheumatol."},{"key":"600_CR99","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","volume":"76","author":"LC Cappelli","year":"2017","unstructured":"Cappelli, L. C. et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann. Rheum. Dis. 76, 43\u201350 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"600_CR100","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","volume":"24","author":"BM Warner","year":"2019","unstructured":"Warner, B. M. et al. Sicca syndrome associated with immune checkpoint inhibitor therapy. Oncologist 24, 1259\u20131269 (2019).","journal-title":"Oncologist"},{"key":"600_CR101","volume":"6","author":"DY Wang","year":"2017","unstructured":"Wang, D. Y., Ye, F., Zhao, S. & Johnson, D. B. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis. Oncoimmunology 6, e1344805 (2017).","journal-title":"Oncoimmunology"},{"key":"600_CR102","doi-asserted-by":"crossref","first-page":"1875639","DOI":"10.1080\/2162402X.2021.1875639","volume":"10","author":"JR Patrinely Jr","year":"2021","unstructured":"Patrinely, J. R. Jr et al. A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. Oncoimmunology 10, 1875639 (2021).","journal-title":"Oncoimmunology"},{"key":"600_CR103","volume":"8","author":"DY Wang","year":"2019","unstructured":"Wang, D. Y. et al. Clinical characterization of colitis arising from anti-PD-1 based therapy. Oncoimmunology 8, e1524695 (2019).","journal-title":"Oncoimmunology"},{"key":"600_CR104","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000958","volume":"8","author":"YR Badran","year":"2020","unstructured":"Badran, Y. R. et al. Immune checkpoint inhibitor-associated celiac disease. J. Immunother. Cancer 8, e000958 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"600_CR105","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1158\/2326-6066.CIR-17-0659","volume":"6","author":"Y Eshet","year":"2018","unstructured":"Eshet, Y. et al. Clinical significance of pancreatic atrophy induced by immune-checkpoint inhibitors: a case-control study. Cancer Immunol. Res. 6, 1453\u20131458 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"600_CR106","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000933","volume":"8","author":"RJ Sullivan","year":"2020","unstructured":"Sullivan, R. J. et al. COVID-19 and immune checkpoint inhibitors: initial considerations. J. Immunother. Cancer 8, e000933 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"600_CR107","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1158\/2326-6066.CIR-18-0717","volume":"7","author":"DB Johnson","year":"2019","unstructured":"Johnson, D. B. et al. Anti-PD-1-induced pneumonitis is associated with persistent imaging abnormalities in melanoma patients. Cancer Immunol. Res. 7, 1755\u20131759 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"600_CR108","doi-asserted-by":"crossref","first-page":"e738","DOI":"10.1016\/j.cllc.2021.01.014","volume":"22","author":"IA Dobre","year":"2021","unstructured":"Dobre, I. A. et al. Outcomes of patients with interstitial lung disease receiving programmed cell death 1 inhibitors: a retrospective case series. Clin. Lung Cancer 22, e738\u2013e744 (2021).","journal-title":"Clin. Lung Cancer"},{"key":"600_CR109","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar8356","volume":"10","author":"LJ Celada","year":"2018","unstructured":"Celada, L. J. et al. PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-\u03b21 production. Sci. Transl. Med. 10, eaar8356 (2018).","journal-title":"Sci. Transl. Med."},{"key":"600_CR110","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejca.2020.02.024","volume":"131","author":"E Chorti","year":"2020","unstructured":"Chorti, E. et al. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: increased rate and mimicker of metastasis. Eur. J. Cancer 131, 18\u201326 (2020).","journal-title":"Eur. J. Cancer"},{"key":"600_CR111","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.52668","volume":"9","author":"LB Tezera","year":"2020","unstructured":"Tezera, L. B. et al. Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-\u03b1. eLife 9, e52668 (2020).","journal-title":"eLife"},{"key":"600_CR112","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s40425-019-0717-7","volume":"7","author":"A Anastasopoulou","year":"2019","unstructured":"Anastasopoulou, A. et al. Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. J. Immunother. Cancer 7, 239 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"600_CR113","volume":"9","author":"S Bae","year":"2021","unstructured":"Bae, S. et al. Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study. J. Immunother. Cancer 9, e002960 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"600_CR114","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi, J. J. et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391, 933 (2018).","journal-title":"Lancet"},{"key":"600_CR115","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood, S. S. et al. Myocarditis in patients treated with immune checkpoint inhibitors. J. Am. Coll. Cardiol. 71, 1755\u20131764 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"600_CR116","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","volume":"140","author":"MP Bonaca","year":"2019","unstructured":"Bonaca, M. P. et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation 140, 80\u201391 (2019).","journal-title":"Circulation"},{"key":"600_CR117","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40425-017-0296-4","volume":"5","author":"TG Norwood","year":"2017","unstructured":"Norwood, T. G. et al. Smoldering myocarditis following immune checkpoint blockade. J. Immunother. Cancer 5, 91 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"600_CR118","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaccao.2021.01.004","volume":"3","author":"S Waliany","year":"2021","unstructured":"Waliany, S. et al. Myocarditis surveillance with high-sensitivity troponin i during cancer treatment with immune checkpoint inhibitors. JACC Cardio. Oncol. 3, 137\u2013139 (2021).","journal-title":"JACC Cardio. Oncol."},{"key":"600_CR119","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007405","volume":"13","author":"E Ammirati","year":"2020","unstructured":"Ammirati, E. et al. Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document. Circ. Heart Fail. 13, e007405 (2020).","journal-title":"Circ. Heart Fail."},{"key":"600_CR120","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11926-019-0811-3","volume":"21","author":"H Kadota","year":"2019","unstructured":"Kadota, H. et al. Immune checkpoint inhibitor-induced myositis: a case report and literature review. Curr. Rheumatol. Rep. 21, 10 (2019).","journal-title":"Curr. Rheumatol. Rep."},{"key":"600_CR121","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s11886-019-1225-6","volume":"21","author":"CK Ala","year":"2019","unstructured":"Ala, C. K., Klein, A. L. & Moslehi, J. J. Cancer treatment-associated pericardial disease: epidemiology, clinical presentation, diagnosis, and management. Curr. Cardiol. Rep. 21, 156 (2019).","journal-title":"Curr. Cardiol. Rep."},{"key":"600_CR122","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem, J. E. et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 19, 1579\u20131589 (2018).","journal-title":"Lancet Oncol."},{"key":"600_CR123","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMra1100265","volume":"375","author":"JJ Moslehi","year":"2016","unstructured":"Moslehi, J. J. Cardiovascular toxic effects of targeted cancer therapies. N. Engl. J. Med. 375, 1457\u20131467 (2016).","journal-title":"N. Engl. J. Med."},{"key":"600_CR124","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1056\/NEJMe1215300","volume":"368","author":"J Moslehi","year":"2013","unstructured":"Moslehi, J. The cardiovascular perils of cancer survivorship. N. Engl. J. Med. 368, 1055\u20131056 (2013).","journal-title":"N. Engl. J. Med."},{"key":"600_CR125","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.tcm.2012.09.008","volume":"23","author":"SM Bair","year":"2013","unstructured":"Bair, S. M., Choueiri, T. K. & Moslehi, J. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends Cardiovasc. Med. 23, 104\u2013113 (2013).","journal-title":"Trends Cardiovasc. Med."},{"key":"600_CR126","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","volume":"7","author":"DB Johnson","year":"2019","unstructured":"Johnson, D. B. et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J. Immunother. Cancer 7, 134 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"600_CR127","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002890","volume":"9","author":"AC Guidon","year":"2021","unstructured":"Guidon, A. C. et al. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J. Immunother. Cancer 9, e002890 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"600_CR128","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1200\/JCO.2013.51.1683","volume":"33","author":"DB Johnson","year":"2015","unstructured":"Johnson, D. B. et al. Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma. J. Clin. Oncol. 33, e122\u2013e124 (2015).","journal-title":"J. Clin. Oncol."},{"key":"600_CR129","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1634\/theoncologist.2018-0359","volume":"24","author":"KL Reynolds","year":"2019","unstructured":"Reynolds, K. L. & Guidon, A. C. Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature. Oncologist 24, 435\u2013443 (2019).","journal-title":"Oncologist"},{"key":"600_CR130","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/14740338.2020.1738382","volume":"19","author":"AM Haugh","year":"2020","unstructured":"Haugh, A. M., Probasco, J. C. & Johnson, D. B. Neurologic complications of immune checkpoint inhibitors. Expert Opin. Drug Saf. 19, 479\u2013488 (2020).","journal-title":"Expert Opin. Drug Saf."},{"key":"600_CR131","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/CJI.0000000000000364","volume":"44","author":"JBE Janssen","year":"2021","unstructured":"Janssen, J. B. E. et al. Immune checkpoint inhibitor-related Guillain-Barr\u00e9 syndrome: a case series and review of the literature. J. Immunother. 44, 276\u2013282 (2021).","journal-title":"J. Immunother."},{"key":"600_CR132","first-page":"e1093","volume":"93","author":"D Dubey","year":"2019","unstructured":"Dubey, D. et al. Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology 93, e1093\u2013e1103 (2019).","journal-title":"Neurology"},{"key":"600_CR133","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1200\/JCO.18.02141","volume":"37","author":"GS Phillips","year":"2019","unstructured":"Phillips, G. S. et al. Treatment outcomes of immune-related cutaneous adverse events. J. Clin. Oncol. 37, 2746\u20132758 (2019).","journal-title":"J. Clin. Oncol."},{"key":"600_CR134","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/bjd.20074","volume":"185","author":"LL Thompson","year":"2021","unstructured":"Thompson, L. L. et al. Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity. Br. J. Dermatol. 185, 627\u2013635 (2021).","journal-title":"Br. J. Dermatol."},{"key":"600_CR135","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/bjd.19313","volume":"183","author":"GE Molina","year":"2020","unstructured":"Molina, G. E., Reynolds, K. L. & Chen, S. T. Diagnostic and therapeutic differences between immune checkpoint inhibitor-induced and idiopathic bullous pemphigoid: a cross-sectional study. Br. J. Dermatol. 183, 1126\u20131128 (2020).","journal-title":"Br. J. Dermatol."},{"key":"600_CR136","volume":"9","author":"MD Lee","year":"2021","unstructured":"Lee, M. D. et al. Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study. J. Immunother. Cancer 9, e002292 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"600_CR137","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","volume":"31","author":"FB Cortazar","year":"2020","unstructured":"Cortazar, F. B. et al. Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J. Am. Soc. Nephrol. 31, 435\u2013446 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"600_CR138","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","volume":"24","author":"EJ Davis","year":"2019","unstructured":"Davis, E. J. et al. Hematologic complications of immune checkpoint inhibitors. Oncologist 24, 584\u2013588 (2019).","journal-title":"Oncologist"},{"key":"600_CR139","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-017-0210-0","volume":"5","author":"E Shiuan","year":"2017","unstructured":"Shiuan, E. et al. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. J. Immunother. Cancer 5, 8 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"600_CR140","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.ophtha.2020.11.001","volume":"128","author":"MM Sun","year":"2021","unstructured":"Sun, M. M. et al. Ophthalmic immune-related adverse events after anti-CTLA-4 or PD-1 therapy recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry. Ophthalmology 128, 910\u2013919 (2021).","journal-title":"Ophthalmology"},{"key":"600_CR141","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/09273948.2020.1781902","volume":"29","author":"ER Dow","year":"2021","unstructured":"Dow, E. R., Yung, M. & Tsui, E. Immune checkpoint inhibitor-associated uveitis: review of treatments and outcomes. Ocul. Immunol. Inflamm. 29, 203\u2013211 (2021).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"600_CR142","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003066","volume":"9","author":"BR Halle","year":"2021","unstructured":"Halle, B. R. et al. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. J. Immunother. Cancer 9, e003066 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"600_CR143","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.19.01674","volume":"38","author":"H Abu-Sbeih","year":"2020","unstructured":"Abu-Sbeih, H. et al. Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease. J. Clin. Oncol. 38, 576\u2013583 (2020).","journal-title":"J. Clin. Oncol."},{"key":"600_CR144","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","volume":"28","author":"AM Menzies","year":"2017","unstructured":"Menzies, A. M. et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann. Oncol. 28, 368\u201376 (2017).","journal-title":"Ann. Oncol."},{"key":"600_CR145","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","volume":"2","author":"DB Johnson","year":"2016","unstructured":"Johnson, D. B. et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2, 234\u2013240 (2016).","journal-title":"JAMA Oncol."},{"key":"600_CR146","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1634\/theoncologist.2019-0659","volume":"25","author":"V Kumar","year":"2020","unstructured":"Kumar, V. et al. The safety and efficacy of checkpoint inhibitors in transplant recipients: a case series and systematic review of literature. Oncologist 25, 505\u2013514 (2020).","journal-title":"Oncologist"},{"key":"600_CR147","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMc1903064","volume":"380","author":"K Esfahani","year":"2019","unstructured":"Esfahani, K. et al. Alemtuzumab for immune-related myocarditis due to PD-1 therapy. N. Engl. J. Med. 380, 2375\u20132376 (2019).","journal-title":"N. Engl. J. Med."},{"key":"600_CR148","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMc1901677","volume":"380","author":"JE Salem","year":"2019","unstructured":"Salem, J. E. et al. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N. Engl. J. Med. 380, 2377\u20132379 (2019).","journal-title":"N. Engl. J. Med."},{"key":"600_CR149","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.annonc.2020.03.285","volume":"31","author":"J Haanen","year":"2020","unstructured":"Haanen, J. et al. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. Ann. Oncol. 31, 724\u2013744 (2020).","journal-title":"Ann. Oncol."},{"key":"600_CR150","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang, D. Y. et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 4, 1721\u20131728 (2018).","journal-title":"JAMA Oncol."},{"key":"600_CR151","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","volume":"26","author":"JP Pignon","year":"2008","unstructured":"Pignon, J. P. et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 26, 3552\u20133559 (2008).","journal-title":"J. Clin. Oncol."},{"key":"600_CR152","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/JCO.2015.62.9345","volume":"34","author":"GV Long","year":"2016","unstructured":"Long, G. V. et al. Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J. Clin. Oncol. 34, 871\u2013878 (2016).","journal-title":"J. Clin. Oncol."},{"key":"600_CR153","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/01.sla.0000217673.04165.ea","volume":"244","author":"JL Cameron","year":"2006","unstructured":"Cameron, J. L., Riall, T. S., Coleman, J. & Belcher, K. A. One thousand consecutive pancreaticoduodenectomies. Ann. Surg. 244, 10\u201315 (2006).","journal-title":"Ann. Surg."},{"key":"600_CR154","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","volume":"363","author":"TA Gooley","year":"2010","unstructured":"Gooley, T. A. et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N. Engl. J. Med. 363, 2091\u20132101 (2010).","journal-title":"N. Engl. J. Med."},{"key":"600_CR155","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","volume":"35","author":"J Naidoo","year":"2017","unstructured":"Naidoo, J. et al. Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy. J. Clin. Oncol. 35, 709\u2013717 (2017).","journal-title":"J. Clin. Oncol."},{"key":"600_CR156","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2051-1426-2-19","volume":"2","author":"C Kyi","year":"2014","unstructured":"Kyi, C. et al. Opportunistic infections in patients treated with immunotherapy for cancer. J. Immunother. Cancer 2, 19 (2014).","journal-title":"J. Immunother. Cancer"},{"key":"600_CR157","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1200\/JCO.21.00079","volume":"39","author":"DJ Olson","year":"2021","unstructured":"Olson, D. J. et al. Pembrolizumab plus ipilimumab following anti-PD-1\/L1 failure in melanoma. J. Clin. Oncol. 39, 2647\u20132655 (2021).","journal-title":"J. Clin. Oncol."},{"key":"600_CR158","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","volume":"383","author":"R Dummer","year":"2020","unstructured":"Dummer, R. et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N. Engl. J. Med. 383, 1139\u20131148 (2020).","journal-title":"N. Engl. J. Med."},{"key":"600_CR159","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","volume":"6","author":"C Dolladille","year":"2020","unstructured":"Dolladille, C. et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 6, 865\u2013871 (2020).","journal-title":"JAMA Oncol."},{"key":"600_CR160","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1158\/2326-6066.CIR-17-0755","volume":"6","author":"FC Santini","year":"2018","unstructured":"Santini, F. C. et al. Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC. Cancer Immunol. Res. 6, 1093\u20131099 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"600_CR161","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1200\/JCO.19.00320","volume":"37","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih, H. et al. Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis. J. Clin. Oncol. 37, 2738\u20132745 (2019).","journal-title":"J. Clin. Oncol."},{"key":"600_CR162","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/annonc\/mdx642","volume":"29","author":"MH Pollack","year":"2018","unstructured":"Pollack, M. H. et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann. Oncol. 29, 250\u2013255 (2018).","journal-title":"Ann. Oncol."},{"key":"600_CR163","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1002\/cncr.33165","volume":"126","author":"M Li","year":"2020","unstructured":"Li, M. et al. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis. Cancer 126, 5088\u20135097 (2020).","journal-title":"Cancer"},{"key":"600_CR164","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s40425-019-0711-0","volume":"7","author":"YR Badran","year":"2019","unstructured":"Badran, Y. R. et al. Concurrent therapy with immune checkpoint inhibitors and TNF\u03b1 blockade in patients with gastrointestinal immune-related adverse events. J. Immunother. Cancer 7, 226 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"600_CR165","volume":"8","author":"F Bertrand","year":"2017","unstructured":"Bertrand, F. et al. TNF\u03b1 blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nat. Commun. 8, 2256 (2017).","journal-title":"Nat. Commun."},{"key":"600_CR166","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1161\/CIRCULATIONAHA.107.709360","volume":"116","author":"N Grabie","year":"2007","unstructured":"Grabie, N. et al. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Circulation 116, 2062\u20132071 (2007).","journal-title":"Circulation"},{"key":"600_CR167","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1172\/JCI31344","volume":"117","author":"I Gotsman","year":"2007","unstructured":"Gotsman, I. et al. Proatherogenic immune responses are regulated by the PD-1\/PD-L pathway in mice. J. Clin. Invest. 117, 2974\u20132982 (2007).","journal-title":"J. Clin. Invest."},{"key":"600_CR168","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/s41591-019-0590-4","volume":"25","author":"DM Fernandez","year":"2019","unstructured":"Fernandez, D. M. et al. Single-cell immune landscape of human atherosclerotic plaques. Nat. Med. 25, 1576\u20131588 (2019).","journal-title":"Nat. Med."},{"key":"600_CR169","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","volume":"142","author":"ZD Drobni","year":"2020","unstructured":"Drobni, Z. D. et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation 142, 2299\u20132311 (2020).","journal-title":"Circulation"},{"key":"600_CR170","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1161\/CIRCULATIONAHA.120.048708","volume":"142","author":"R Calabretta","year":"2020","unstructured":"Calabretta, R. et al. Immune checkpoint inhibitor therapy induces inflammatory activity in large arteries. Circulation 142, 2396\u20132398 (2020).","journal-title":"Circulation"},{"key":"600_CR171","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","volume":"592","author":"P Libby","year":"2021","unstructured":"Libby, P. The changing landscape of atherosclerosis. Nature 592, 524\u2013533 (2021).","journal-title":"Nature"},{"key":"600_CR172","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/j.cllc.2020.07.016","volume":"22","author":"MS Oh","year":"2021","unstructured":"Oh, M. S. et al. The impact of beta blockers on survival outcomes in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors. Clin. Lung Cancer 22, e57\u2013e62 (2021).","journal-title":"Clin. Lung Cancer"},{"key":"600_CR173","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.amjcard.2020.02.016","volume":"125","author":"O Oren","year":"2020","unstructured":"Oren, O. et al. Cardiovascular health and outcomes in cancer patients receiving immune checkpoint inhibitors. Am. J. Cardiol. 125, 1920\u20131926 (2020).","journal-title":"Am. J. Cardiol."},{"key":"600_CR174","doi-asserted-by":"crossref","first-page":"e602","DOI":"10.1634\/theoncologist.2019-0518","volume":"25","author":"DY Wang","year":"2020","unstructured":"Wang, D. Y. et al. The impact of nonsteroidal anti-inflammatory drugs, beta blockers, and metformin on the efficacy of anti-PD-1 therapy in advanced melanoma. Oncologist 25, e602\u2013e605 (2020).","journal-title":"Oncologist"},{"key":"600_CR175","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139793","volume":"6","author":"CE Porsche","year":"2021","unstructured":"Porsche, C. E. et al. Obesity results in adipose tissue T cell exhaustion. JCI Insight 6, e139793 (2021).","journal-title":"JCI Insight"},{"key":"600_CR176","doi-asserted-by":"crossref","first-page":"G211","DOI":"10.1152\/ajpgi.00040.2019","volume":"318","author":"DA Breuer","year":"2020","unstructured":"Breuer, D. A. et al. CD8(+) T cells regulate liver injury in obesity-related nonalcoholic fatty liver disease. Am. J. Physiol. Gastrointest. Liver Physiol. 318, G211\u2013G224 (2020).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"600_CR177","doi-asserted-by":"crossref","first-page":"109285","DOI":"10.1016\/j.celrep.2021.109285","volume":"35","author":"AK Pingili","year":"2021","unstructured":"Pingili, A. K. et al. Immune checkpoint blockade reprograms systemic immune landscape and tumor microenvironment in obesity-associated breast cancer. Cell Rep. 35, 109285 (2021).","journal-title":"Cell Rep."},{"key":"600_CR178","volume":"8","author":"B Wu","year":"2020","unstructured":"Wu, B. et al. Genetic ablation of adipocyte PD-L1 reduces tumor growth but accentuates obesity-associated inflammation. J. Immunother. Cancer 8, e000964 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"600_CR179","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","volume":"19","author":"JL McQuade","year":"2018","unstructured":"McQuade, J. L. et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 19, 310\u2013322 (2018).","journal-title":"Lancet Oncol."},{"key":"600_CR180","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40425-019-0527-y","volume":"7","author":"A Cortellini","year":"2019","unstructured":"Cortellini, A. et al. A multicenter study of body mass index in cancer patients treated with anti-PD-1\/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. J. Immunother. Cancer 7, 57 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"600_CR181","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000821","volume":"8","author":"AC Young","year":"2020","unstructured":"Young, A. C. et al. Impact of body composition on outcomes from anti-PD1 +\/\u2212 anti-CTLA-4 treatment in melanoma. J. Immunother. Cancer 8, e000821 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"600_CR182","volume":"8","author":"SK Boi","year":"2020","unstructured":"Boi, S. K. et al. Obesity diminishes response to PD-1-based immunotherapies in renal cancer. J. Immunother. Cancer 8, e000725 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"600_CR183","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2019.12.031","volume":"128","author":"A Cortellini","year":"2020","unstructured":"Cortellini, A. et al. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)\/programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: a multicentre analysis of immune-related adverse events. Eur. J. Cancer 128, 17\u201326 (2020).","journal-title":"Eur. J. Cancer"},{"key":"600_CR184","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1530\/EJE-20-1362","volume":"184","author":"A Leiter","year":"2021","unstructured":"Leiter, A. et al. Metabolic disease and adverse events from immune checkpoint inhibitors. Eur. J. Endocrinol. 184, 857\u2013865 (2021).","journal-title":"Eur. J. Endocrinol."},{"key":"600_CR185","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s10637-017-0464-x","volume":"35","author":"V Heidelberger","year":"2017","unstructured":"Heidelberger, V. et al. Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients. Invest. N. Drugs 35, 436\u2013441 (2017).","journal-title":"Invest. N. Drugs"},{"key":"600_CR186","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/14728222.2021.1869213","volume":"25","author":"JE Kim","year":"2021","unstructured":"Kim, J. E., Patel, K. & Jackson, C. M. The potential for immune checkpoint modulators in cerebrovascular injury and inflammation. Expert Opin. Ther. Targets 25, 101\u2013113 (2021).","journal-title":"Expert Opin. Ther. Targets"},{"key":"600_CR187","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1161\/STROKEAHA.115.010592","volume":"46","author":"S Bodhankar","year":"2015","unstructured":"Bodhankar, S. et al. PD-L1 monoclonal antibody treats ischemic stroke by controlling central nervous system inflammation. Stroke 46, 2926\u20132934 (2015).","journal-title":"Stroke"},{"key":"600_CR188","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1161\/STROKEAHA.111.613182","volume":"42","author":"X Ren","year":"2011","unstructured":"Ren, X. et al. Programmed death-1 pathway limits central nervous system inflammation and neurologic deficits in murine experimental stroke. Stroke 42, 2578\u20132583 (2011).","journal-title":"Stroke"},{"key":"600_CR189","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nm.4022","volume":"22","author":"K Baruch","year":"2016","unstructured":"Baruch, K. et al. PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer\u2019s disease. Nat. Med. 22, 135\u2013137 (2016).","journal-title":"Nat. Med."},{"key":"600_CR190","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-08352-5","volume":"10","author":"N Rosenzweig","year":"2019","unstructured":"Rosenzweig, N. et al. PD-1\/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model. Nat. Commun. 10, 465 (2019).","journal-title":"Nat. Commun."},{"key":"600_CR191","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","volume":"37","author":"EB Garon","year":"2019","unstructured":"Garon, E. B. et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J. Clin. Oncol. 37, 2518\u20132527 (2019).","journal-title":"J. Clin. Oncol."},{"key":"600_CR192","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck, M. et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u226550%. J. Clin. Oncol. 39, 2339\u20132349 (2021).","journal-title":"J. Clin. Oncol."},{"key":"600_CR193","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-001079","volume":"5","author":"L Albiges","year":"2020","unstructured":"Albiges, L. et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 5, e001079 (2020).","journal-title":"ESMO Open"},{"key":"600_CR194","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","volume":"21","author":"PA Ascierto","year":"2020","unstructured":"Ascierto, P. A. et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB\u2013C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 21, 1465\u20131477 (2020).","journal-title":"Lancet Oncol."},{"key":"600_CR195","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","volume":"22","author":"AMM Eggermont","year":"2021","unstructured":"Eggermont, A. M. M. et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 22, 643\u2013654 (2021).","journal-title":"Lancet Oncol."},{"issue":"15 Suppl.","key":"600_CR196","doi-asserted-by":"crossref","first-page":"8511","DOI":"10.1200\/JCO.2021.39.15_suppl.8511","volume":"39","author":"DR Spigel","year":"2021","unstructured":"Spigel, D. R. et al. Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: an update from the PACIFIC trial [abstract]. J. Clin. Oncol. 39 (15 Suppl.), 8511 (2021).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-022-00600-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-022-00600-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-022-00600-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T17:50:05Z","timestamp":1733939405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-022-00600-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,26]]},"references-count":196,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["600"],"URL":"https:\/\/doi.org\/10.1038\/s41571-022-00600-w","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,26]]},"assertion":[{"value":"4 January 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.B.J. has acted as a consultant and\/or advisor for BMS, Catalyst, Iovance, Jansen, Mallinckrodt, Merck, Mosaic ImmunoEngineering, Novartis, Oncosec, Pfizer and Targovax, and receives research funding from BMS and Incyte. D.B.J. and J.J.M. have a patent pending for use of abatacept to reverse ICI toxicities. D.B.J. and J.M.B. have a patent pending for use of MHC II as a biomarker for ICI response. J.M.B. receives research funding from Genentech and Incyte. C.A.N. and J.J.M. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}